AU2022387053A1 - Treatment of treatment resistant depression with psilocybin - Google Patents

Info

Publication number

AU2022387053A1

AU2022387053A1 AU2022387053A AU2022387053A AU2022387053A1 AU 2022387053 A1 AU2022387053 A1 AU 2022387053A1 AU 2022387053 A AU2022387053 A AU 2022387053A AU 2022387053 A AU2022387053 A AU 2022387053A AU 2022387053 A1 AU2022387053 A1 AU 2022387053A1

Authority

AU

Australia

Prior art keywords

psilocybin

dose

subject

weeks

administering

Prior art date

2021-11-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 title claims abstract description 992
• QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 title claims abstract description 981
• 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 title claims abstract description 54
• 238000011282 treatment Methods 0.000 title claims description 234
• 238000000034 method Methods 0.000 claims abstract description 392
• 208000024891 symptom Diseases 0.000 claims description 111
• 230000008859 change Effects 0.000 claims description 106
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 61
• 239000008194 pharmaceutical composition Substances 0.000 claims description 55
• 230000003001 depressive effect Effects 0.000 claims description 36
• 238000004128 high performance liquid chromatography Methods 0.000 claims description 35
• 239000000935 antidepressant agent Substances 0.000 claims description 32
• 230000001430 anti-depressive effect Effects 0.000 claims description 31
• 239000012535 impurity Substances 0.000 claims description 29
• 229940005513 antidepressants Drugs 0.000 claims description 28
• 239000000126 substance Substances 0.000 claims description 25
• 206010054089 Depressive symptom Diseases 0.000 claims description 24
• 238000011156 evaluation Methods 0.000 claims description 24
• 230000009467 reduction Effects 0.000 claims description 24
• 206010010144 Completed suicide Diseases 0.000 claims description 23
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 18
• 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 18
• 206010042458 Suicidal ideation Diseases 0.000 claims description 16
• 206010042464 Suicide attempt Diseases 0.000 claims description 15
• 229920000881 Modified starch Polymers 0.000 claims description 14
• 230000000977 initiatory effect Effects 0.000 claims description 7
• 230000002265 prevention Effects 0.000 claims description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 100
• GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 98
• 208000019901 Anxiety disease Diseases 0.000 description 67
• 208000035475 disorder Diseases 0.000 description 60
• 238000012360 testing method Methods 0.000 description 58
• 230000036506 anxiety Effects 0.000 description 56
• 239000003814 drug Substances 0.000 description 54
• 230000000694 effects Effects 0.000 description 52
• 230000004044 response Effects 0.000 description 49
• 229940079593 drug Drugs 0.000 description 47
• 201000010099 disease Diseases 0.000 description 40
• 230000001225 therapeutic effect Effects 0.000 description 39
• 230000007423 decrease Effects 0.000 description 36
• 238000001938 differential scanning calorimetry curve Methods 0.000 description 34
• 238000012216 screening Methods 0.000 description 30
• 239000006186 oral dosage form Substances 0.000 description 29
• 229920003109 sodium starch glycolate Polymers 0.000 description 29
• 229940079832 sodium starch glycolate Drugs 0.000 description 29
• 239000008109 sodium starch glycolate Substances 0.000 description 29
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
• 208000020401 Depressive disease Diseases 0.000 description 26
• 238000002483 medication Methods 0.000 description 26
• 230000002459 sustained effect Effects 0.000 description 26
• 230000010354 integration Effects 0.000 description 25
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 24
• 230000002996 emotional effect Effects 0.000 description 24
• 230000002411 adverse Effects 0.000 description 23
• 208000024714 major depressive disease Diseases 0.000 description 22
• 239000002775 capsule Substances 0.000 description 21
• 238000012545 processing Methods 0.000 description 21
• 238000002560 therapeutic procedure Methods 0.000 description 21
• 230000008451 emotion Effects 0.000 description 20
• 230000008569 process Effects 0.000 description 19
• 206010060933 Adverse event Diseases 0.000 description 18
• 230000006399 behavior Effects 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 16
• 239000000203 mixture Substances 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• 229940049706 benzodiazepine Drugs 0.000 description 15
• 239000007884 disintegrant Substances 0.000 description 15
• 230000036651 mood Effects 0.000 description 15
• SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 description 14
• 238000009472 formulation Methods 0.000 description 14
• 239000000651 prodrug Substances 0.000 description 14
• 229940002612 prodrug Drugs 0.000 description 14
• ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 description 14
• 230000009471 action Effects 0.000 description 13
• 230000001154 acute effect Effects 0.000 description 13
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 13
• 206010026749 Mania Diseases 0.000 description 12
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 12
• 150000001557 benzodiazepines Chemical class 0.000 description 12
• ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 12
• 230000001149 cognitive effect Effects 0.000 description 12
• 230000002354 daily effect Effects 0.000 description 12
• 230000001337 psychedelic effect Effects 0.000 description 12
• 230000035807 sensation Effects 0.000 description 12
• 206010049119 Emotional distress Diseases 0.000 description 11
• 238000001035 drying Methods 0.000 description 11
• 230000006872 improvement Effects 0.000 description 11
• 230000029058 respiratory gaseous exchange Effects 0.000 description 11
• 206010012374 Depressed mood Diseases 0.000 description 10
• 238000005481 NMR spectroscopy Methods 0.000 description 10
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 10
• 239000005557 antagonist Substances 0.000 description 10
• 230000036528 appetite Effects 0.000 description 10
• 235000019789 appetite Nutrition 0.000 description 10
• 239000000090 biomarker Substances 0.000 description 10
• 230000019771 cognition Effects 0.000 description 10
• 230000003203 everyday effect Effects 0.000 description 10
• 210000001508 eye Anatomy 0.000 description 10
• 230000036541 health Effects 0.000 description 10
• 229940091250 magnesium supplement Drugs 0.000 description 10
• 239000000546 pharmaceutical excipient Substances 0.000 description 10
• 239000002243 precursor Substances 0.000 description 10
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 10
• 230000000007 visual effect Effects 0.000 description 10
• 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 9
• 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 9
• 206010011971 Decreased interest Diseases 0.000 description 9
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
• 208000002193 Pain Diseases 0.000 description 9
• 206010065604 Suicidal behaviour Diseases 0.000 description 9
• 230000006735 deficit Effects 0.000 description 9
• 238000004090 dissolution Methods 0.000 description 9
• 230000009977 dual effect Effects 0.000 description 9
• 206010022437 insomnia Diseases 0.000 description 9
• 239000011777 magnesium Substances 0.000 description 9
• 229910052749 magnesium Inorganic materials 0.000 description 9
• 238000011160 research Methods 0.000 description 9
• 230000001755 vocal effect Effects 0.000 description 9
• AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 8
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
• 201000009916 Postpartum depression Diseases 0.000 description 8
• 208000001431 Psychomotor Agitation Diseases 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 8
• 239000000556 agonist Substances 0.000 description 8
• IGHTZQUIFGUJTG-UHFFFAOYSA-N cannabicyclol Chemical compound O1C2=CC(CCCCC)=CC(O)=C2C2C(C)(C)C3C2C1(C)CC3 IGHTZQUIFGUJTG-UHFFFAOYSA-N 0.000 description 8
• QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 8
• 229950011318 cannabidiol Drugs 0.000 description 8
• 239000013078 crystal Substances 0.000 description 8
• 238000002425 crystallisation Methods 0.000 description 8
• 230000034994 death Effects 0.000 description 8
• PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 8
• 229960003512 nicotinic acid Drugs 0.000 description 8
• 235000001968 nicotinic acid Nutrition 0.000 description 8
• 239000011664 nicotinic acid Substances 0.000 description 8
• 208000020016 psychiatric disease Diseases 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 230000004584 weight gain Effects 0.000 description 8
• 230000004580 weight loss Effects 0.000 description 8
• 208000020925 Bipolar disease Diseases 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 208000011688 Generalised anxiety disease Diseases 0.000 description 7
• 206010019233 Headaches Diseases 0.000 description 7
• 206010022998 Irritability Diseases 0.000 description 7
• 208000028017 Psychotic disease Diseases 0.000 description 7
• 206010038743 Restlessness Diseases 0.000 description 7
• 208000028683 bipolar I disease Diseases 0.000 description 7
• 230000036772 blood pressure Effects 0.000 description 7
• 208000030963 borderline personality disease Diseases 0.000 description 7
• 230000008025 crystallization Effects 0.000 description 7
• 230000009429 distress Effects 0.000 description 7
• 230000000857 drug effect Effects 0.000 description 7
• 238000002635 electroconvulsive therapy Methods 0.000 description 7
• 206010016256 fatigue Diseases 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 230000014509 gene expression Effects 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000007958 sleep Effects 0.000 description 7
• 230000007596 spatial working memory Effects 0.000 description 7
• 206010001497 Agitation Diseases 0.000 description 6
• 206010016374 Feelings of worthlessness Diseases 0.000 description 6
• 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
• 230000005856 abnormality Effects 0.000 description 6
• 238000013019 agitation Methods 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 6
• 238000004891 communication Methods 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 239000000945 filler Substances 0.000 description 6
• 231100000869 headache Toxicity 0.000 description 6
• 230000033001 locomotion Effects 0.000 description 6
• 230000007774 longterm Effects 0.000 description 6
• 238000007726 management method Methods 0.000 description 6
• 230000036407 pain Effects 0.000 description 6
• 230000003442 weekly effect Effects 0.000 description 6
• 230000036642 wellbeing Effects 0.000 description 6
• 230000003936 working memory Effects 0.000 description 6
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 5
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 5
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 5
• 208000025748 atypical depressive disease Diseases 0.000 description 5
• 208000022257 bipolar II disease Diseases 0.000 description 5
• 239000003557 cannabinoid Substances 0.000 description 5
• 229930003827 cannabinoid Natural products 0.000 description 5
• 206010007776 catatonia Diseases 0.000 description 5
• 230000007717 exclusion Effects 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 230000015654 memory Effects 0.000 description 5
• 230000003340 mental effect Effects 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 5
• 230000002085 persistent effect Effects 0.000 description 5
• -1 povidone Chemical compound 0.000 description 5
• 230000002035 prolonged effect Effects 0.000 description 5
• 229940127558 rescue medication Drugs 0.000 description 5
• 208000012672 seasonal affective disease Diseases 0.000 description 5
• 230000001568 sexual effect Effects 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 238000001757 thermogravimetry curve Methods 0.000 description 5
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
• 235000019786 weight gain Nutrition 0.000 description 5
• RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 4
• ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 4
• YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 4
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
• 208000008035 Back Pain Diseases 0.000 description 4
• 208000011597 CGF1 Diseases 0.000 description 4
• UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 4
• UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 4
• WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 4
• REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 4
• VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 4
• ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 description 4
• ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 4
• ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 4
• 206010015535 Euphoric mood Diseases 0.000 description 4
• 208000004547 Hallucinations Diseases 0.000 description 4
• 238000003109 Karl Fischer titration Methods 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 241001062357 Psilocybe cubensis Species 0.000 description 4
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 4
• 206010043169 Tearfulness Diseases 0.000 description 4
• 230000001133 acceleration Effects 0.000 description 4
• 208000024823 antisocial personality disease Diseases 0.000 description 4
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 230000001914 calming effect Effects 0.000 description 4
• WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 4
• REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 4
• QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 4
• QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 4
• YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 4
• 229960003453 cannabinol Drugs 0.000 description 4
• SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 4
• 238000009225 cognitive behavioral therapy Methods 0.000 description 4
• 208000026725 cyclothymic disease Diseases 0.000 description 4
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 230000003292 diminished effect Effects 0.000 description 4
• 229960004242 dronabinol Drugs 0.000 description 4
• 230000008921 facial expression Effects 0.000 description 4
• 208000029364 generalized anxiety disease Diseases 0.000 description 4
• 239000011521 glass Substances 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• 206010020765 hypersomnia Diseases 0.000 description 4
• 238000003384 imaging method Methods 0.000 description 4
• 230000002045 lasting effect Effects 0.000 description 4
• 235000012054 meals Nutrition 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 230000008447 perception Effects 0.000 description 4
• 238000001671 psychotherapy Methods 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 208000019116 sleep disease Diseases 0.000 description 4
• 230000004039 social cognition Effects 0.000 description 4
• 239000012453 solvate Substances 0.000 description 4
• 238000011287 therapeutic dose Methods 0.000 description 4
• 230000004797 therapeutic response Effects 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 3
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
• 238000004679 31P NMR spectroscopy Methods 0.000 description 3
• 206010067484 Adverse reaction Diseases 0.000 description 3
• 206010050012 Bradyphrenia Diseases 0.000 description 3
• 102000001554 Hemoglobins Human genes 0.000 description 3
• 108010054147 Hemoglobins Proteins 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 206010027940 Mood altered Diseases 0.000 description 3
• DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 3
• COSPVUFTLGQDQL-UHFFFAOYSA-N Nelotanserin Chemical compound C1=C(C=2N(N=CC=2Br)C)C(OC)=CC=C1NC(=O)NC1=CC=C(F)C=C1F COSPVUFTLGQDQL-UHFFFAOYSA-N 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 230000006838 adverse reaction Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 229940124604 anti-psychotic medication Drugs 0.000 description 3
• 239000000164 antipsychotic agent Substances 0.000 description 3
• 229940005529 antipsychotics Drugs 0.000 description 3
• 239000002249 anxiolytic agent Substances 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 230000003920 cognitive function Effects 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 230000001010 compromised effect Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 238000002598 diffusion tensor imaging Methods 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 239000012767 functional filler Substances 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 238000011031 large-scale manufacturing process Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 229960004391 lorazepam Drugs 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 238000013160 medical therapy Methods 0.000 description 3
• 229940016286 microcrystalline cellulose Drugs 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• 239000008108 microcrystalline cellulose Substances 0.000 description 3
• 238000003058 natural language processing Methods 0.000 description 3
• 230000003557 neuropsychological effect Effects 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 238000013439 planning Methods 0.000 description 3
• 208000028173 post-traumatic stress disease Diseases 0.000 description 3
• 210000002442 prefrontal cortex Anatomy 0.000 description 3
• 239000003196 psychodysleptic agent Substances 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 208000022925 sleep disturbance Diseases 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 229940032147 starch Drugs 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 208000011117 substance-related disease Diseases 0.000 description 3
• 230000003319 supportive effect Effects 0.000 description 3
• 230000003867 tiredness Effects 0.000 description 3
• 208000016255 tiredness Diseases 0.000 description 3
• 230000000472 traumatic effect Effects 0.000 description 3
• 230000002618 waking effect Effects 0.000 description 3
• ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 description 2
• IXJXRDCCQRZSDV-GCKMJXCFSA-N (6ar,9r,10as)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6h-1,9-epoxybenzo[c]chromene Chemical compound C1C[C@@H](C(O2)(C)C)[C@@H]3C[C@]1(C)OC1=C3C2=CC(CCCCC)=C1 IXJXRDCCQRZSDV-GCKMJXCFSA-N 0.000 description 2
• HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 2
• GEICAQNIOJFRQN-UHFFFAOYSA-N 9-aminomethyl-9,10-dihydroanthracene Chemical compound C1=CC=C2C(CN)C3=CC=CC=C3CC2=C1 GEICAQNIOJFRQN-UHFFFAOYSA-N 0.000 description 2
• 206010050013 Abulia Diseases 0.000 description 2
• 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
• 108010082126 Alanine transaminase Proteins 0.000 description 2
• 206010001854 Altered state of consciousness Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• 108010074051 C-Reactive Protein Proteins 0.000 description 2
• 102100032752 C-reactive protein Human genes 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 description 2
• 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
• 208000006561 Cluster Headache Diseases 0.000 description 2
• 229920002785 Croscarmellose sodium Polymers 0.000 description 2
• UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 2
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
• 241001125671 Eretmochelys imbricata Species 0.000 description 2
• 206010021403 Illusion Diseases 0.000 description 2
• 206010022524 Intentional self-injury Diseases 0.000 description 2
• VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
• 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
• 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 description 2
• 206010033864 Paranoia Diseases 0.000 description 2
• 208000027099 Paranoid disease Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 2
• 206010041250 Social phobia Diseases 0.000 description 2
• 208000028790 Speech Sound disease Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 2
• 208000030886 Traumatic Brain injury Diseases 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 229960004538 alprazolam Drugs 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 210000004727 amygdala Anatomy 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 230000000949 anxiolytic effect Effects 0.000 description 2
• 229940005530 anxiolytics Drugs 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 230000037007 arousal Effects 0.000 description 2
• 230000003190 augmentative effect Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 238000004820 blood count Methods 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 230000036760 body temperature Effects 0.000 description 2
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
• 229940065144 cannabinoids Drugs 0.000 description 2
• 239000007963 capsule composition Substances 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 229960001681 croscarmellose sodium Drugs 0.000 description 2
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
• 208000017004 dementia pugilistica Diseases 0.000 description 2
• 230000000994 depressogenic effect Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 208000024732 dysthymic disease Diseases 0.000 description 2
• 235000005686 eating Nutrition 0.000 description 2
• VAIOZOCLKVMIMN-PRJWTAEASA-N eplivanserin Chemical compound C=1C=CC=C(F)C=1\C(=N/OCCN(C)C)\C=C\C1=CC=C(O)C=C1 VAIOZOCLKVMIMN-PRJWTAEASA-N 0.000 description 2
• 229950000789 eplivanserin Drugs 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 230000004438 eyesight Effects 0.000 description 2
• 229940014144 folate Drugs 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 239000011724 folic acid Substances 0.000 description 2
• 230000009760 functional impairment Effects 0.000 description 2
• 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
• 230000001505 hypomanic effect Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000010365 information processing Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000009434 installation Methods 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• 229960003208 levomefolic acid Drugs 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 229950002454 lysergide Drugs 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229940126601 medicinal product Drugs 0.000 description 2
• 230000004630 mental health Effects 0.000 description 2
• 230000006996 mental state Effects 0.000 description 2
• RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
• 230000007510 mood change Effects 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 208000013465 muscle pain Diseases 0.000 description 2
• 210000004165 myocardium Anatomy 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 229950006103 nelotanserin Drugs 0.000 description 2
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• AXNGJCOYCMDPQG-UHFFFAOYSA-N phenyl-[1-(2-phenylethyl)-4-piperidinyl]methanol Chemical compound C=1C=CC=CC=1C(O)C(CC1)CCN1CCC1=CC=CC=C1 AXNGJCOYCMDPQG-UHFFFAOYSA-N 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 229940069328 povidone Drugs 0.000 description 2
• 229960004856 prazepam Drugs 0.000 description 2
• 238000002369 psychoeducation Methods 0.000 description 2
• 230000000506 psychotropic effect Effects 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000036387 respiratory rate Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 229960001534 risperidone Drugs 0.000 description 2
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 230000000862 serotonergic effect Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000016686 tic disease Diseases 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 238000011491 transcranial magnetic stimulation Methods 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000009529 traumatic brain injury Effects 0.000 description 2
• 238000010200 validation analysis Methods 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• LMUVYJCAFWGNSY-VIFPVBQESA-N (3s)-5-(2-chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(C=C11)[N+]([O-])=O)=O)C)=C1C1=CC=CC=C1Cl LMUVYJCAFWGNSY-VIFPVBQESA-N 0.000 description 1
• FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
• GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
• VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
• WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
• DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
• OGMGYKPECFQXJJ-UHFFFAOYSA-N 1-[2-(3,4-dihydro-1h-isochromen-1-yl)ethyl]-4-(4-fluorophenyl)piperazine;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1N1CCN(CCC2C3=CC=CC=C3CCO2)CC1 OGMGYKPECFQXJJ-UHFFFAOYSA-N 0.000 description 1
• OYRPNABWTHDOFK-UHFFFAOYSA-N 1-methyl-8-nitro-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound C12=CC([N+]([O-])=O)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 OYRPNABWTHDOFK-UHFFFAOYSA-N 0.000 description 1
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
• ZDYRCUZZLRLMHG-UHFFFAOYSA-N 2-chloro-4-(o-fluorophenyl)-9-methyl-6h-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine Chemical compound C1=2C=C(Cl)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1F ZDYRCUZZLRLMHG-UHFFFAOYSA-N 0.000 description 1
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
• QRWVNMAJJIQCEG-UHFFFAOYSA-N 3-hydroxy-1-methyl-7-nitro-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound CN1C(C(N=C(C2=C1C=CC(=C2)[N+](=O)[O-])C2=CC=CC=C2)O)=O QRWVNMAJJIQCEG-UHFFFAOYSA-N 0.000 description 1
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
• NQSSWDKQLVBUQN-UHFFFAOYSA-N 4-(2-chlorophenyl)-2-ethyl-6h-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepine Chemical compound S1C(CC)=CC2=C1N1C=NN=C1CN=C2C1=CC=CC=C1Cl NQSSWDKQLVBUQN-UHFFFAOYSA-N 0.000 description 1
• 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 description 1
• UHFIFTRHLBAWGY-UHFFFAOYSA-N 5-(2-fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1F UHFIFTRHLBAWGY-UHFFFAOYSA-N 0.000 description 1
• RDLAGIOILLWVTM-UHFFFAOYSA-N 6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound [N+](=O)([O-])C=1C=CC2=C(C(=NCC=3N2C(=NN=3)C)C2=C(C=CC=C2)F)C=1 RDLAGIOILLWVTM-UHFFFAOYSA-N 0.000 description 1
• CGMJQQJSWIRRRL-UHFFFAOYSA-N 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound ClC1=CC=CC=C1C1=NCC(=O)NC2=CC=C(Br)C=C12 CGMJQQJSWIRRRL-UHFFFAOYSA-N 0.000 description 1
• KCEIOBKDDQAYCM-UHFFFAOYSA-N 8-bromo-1-methyl-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 KCEIOBKDDQAYCM-UHFFFAOYSA-N 0.000 description 1
• MPZVLJCMGPYWQQ-UHFFFAOYSA-N 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1F MPZVLJCMGPYWQQ-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• 206010001540 Akathisia Diseases 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• SMYALUSCZJXWHG-UHFFFAOYSA-N Altanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=S)=O)CC1 SMYALUSCZJXWHG-UHFFFAOYSA-N 0.000 description 1
• 208000031091 Amnestic disease Diseases 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 208000007415 Anhedonia Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• 206010002869 Anxiety symptoms Diseases 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 206010003504 Aspiration Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 206010074080 Autoscopy Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 206010006312 Breast swelling Diseases 0.000 description 1
• 206010006313 Breast tenderness Diseases 0.000 description 1
• VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 208000003417 Central Sleep Apnea Diseases 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 208000027521 Childhood-Onset Fluency disease Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 102100034761 Cilia- and flagella-associated protein 418 Human genes 0.000 description 1
• CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
• 208000022497 Cocaine-Related disease Diseases 0.000 description 1
• 208000027691 Conduct disease Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 208000019736 Cranial nerve disease Diseases 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 206010011469 Crying Diseases 0.000 description 1
• 229910002483 Cu Ka Inorganic materials 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 208000024254 Delusional disease Diseases 0.000 description 1
• 206010012258 Delusional perception Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010013142 Disinhibition Diseases 0.000 description 1
• 208000025967 Dissociative Identity disease Diseases 0.000 description 1
• 206010013486 Distractibility Diseases 0.000 description 1
• 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
• 206010013634 Dreamy state Diseases 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 206010013954 Dysphoria Diseases 0.000 description 1
• 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
• 208000033618 Elevated mood Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 208000027534 Emotional disease Diseases 0.000 description 1
• CUCHJCMWNFEYOM-UHFFFAOYSA-N Ethyl loflazepate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)N=C1C1=CC=CC=C1F CUCHJCMWNFEYOM-UHFFFAOYSA-N 0.000 description 1
• VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
• 241001539473 Euphoria Species 0.000 description 1
• 208000035874 Excoriation Diseases 0.000 description 1
• 208000026097 Factitious disease Diseases 0.000 description 1
• 206010016275 Fear Diseases 0.000 description 1
• 206010016322 Feeling abnormal Diseases 0.000 description 1
• 208000001836 Firesetting Behavior Diseases 0.000 description 1
• WMFSSTNVXWNLKI-UHFFFAOYSA-N Flutazolam Chemical compound O1CCN2CC(=O)N(CCO)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1F WMFSSTNVXWNLKI-UHFFFAOYSA-N 0.000 description 1
• 206010056465 Food craving Diseases 0.000 description 1
• 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
• 241001069765 Fridericia <angiosperm> Species 0.000 description 1
• 208000001613 Gambling Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• 208000014513 Hoarding disease Diseases 0.000 description 1
• 101100439214 Homo sapiens CFAP418 gene Proteins 0.000 description 1
• 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
• 206010020400 Hostility Diseases 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010020559 Hyperacusis Diseases 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010021588 Inappropriate affect Diseases 0.000 description 1
• 206010022035 Initial insomnia Diseases 0.000 description 1
• 201000006347 Intellectual Disability Diseases 0.000 description 1
• 206010063385 Intellectualisation Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
• BJIPVHLRWSDKOS-UHFFFAOYSA-N LY-367,265 Chemical compound C1=2C3=CC=CC=2CCCN1S(=O)(=O)N3CCN(CC1)CC=C1C1=CNC2=CC(F)=CC=C21 BJIPVHLRWSDKOS-UHFFFAOYSA-N 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 206010024419 Libido decreased Diseases 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 201000000251 Locked-in syndrome Diseases 0.000 description 1
• 206010024796 Logorrhoea Diseases 0.000 description 1
• 206010025429 Magical thinking Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000003863 Marijuana Abuse Diseases 0.000 description 1
• YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
• 206010027374 Mental impairment Diseases 0.000 description 1
• JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 206010027951 Mood swings Diseases 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 206010049816 Muscle tightness Diseases 0.000 description 1
• 206010028403 Mutism Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• XHLOUFPZLUULGI-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-2-(5-methoxy-1H-indol-3-yl)ethanamine Chemical compound C12=CC(OC)=CC=C2NC=C1CCNCC1=CC=C(Br)C=C1 XHLOUFPZLUULGI-UHFFFAOYSA-N 0.000 description 1
• 206010029216 Nervousness Diseases 0.000 description 1
• 208000027626 Neurocognitive disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 208000012898 Olfaction disease Diseases 0.000 description 1
• 208000026251 Opioid-Related disease Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010033664 Panic attack Diseases 0.000 description 1
• 206010034018 Parosmia Diseases 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• 206010056238 Phantom pain Diseases 0.000 description 1
• QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• 208000032128 Phonological disease Diseases 0.000 description 1
• 206010034960 Photophobia Diseases 0.000 description 1
• 241001482237 Pica Species 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000024777 Prion disease Diseases 0.000 description 1
• AQRLDDAFYYAIJP-UHFFFAOYSA-N Pruvanserin Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 AQRLDDAFYYAIJP-UHFFFAOYSA-N 0.000 description 1
• 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• 206010037213 Psychomotor retardation Diseases 0.000 description 1
• IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
• 208000030988 Schizoid Personality disease Diseases 0.000 description 1
• 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
• 206010039917 Selective mutism Diseases 0.000 description 1
• 206010040026 Sensory disturbance Diseases 0.000 description 1
• 208000000810 Separation Anxiety Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• 206010062684 Somatic hallucination Diseases 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 208000014604 Specific Language disease Diseases 0.000 description 1
• 208000003028 Stuttering Diseases 0.000 description 1
• 206010064093 Suggestibility Diseases 0.000 description 1
• 208000035239 Synesthesia Diseases 0.000 description 1
• 206010064805 Tachyphrenia Diseases 0.000 description 1
• SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
• 208000008548 Tension-Type Headache Diseases 0.000 description 1
• 206010043431 Thinking abnormal Diseases 0.000 description 1
• 206010074073 Time perception altered Diseases 0.000 description 1
• 208000009205 Tinnitus Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
• 241001147416 Ursus maritimus Species 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 229930003779 Vitamin B12 Natural products 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000004308 accommodation Effects 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 238000001994 activation Methods 0.000 description 1
• 229950008881 adatanserin Drugs 0.000 description 1
• HPFLVTSWRFCPCV-UHFFFAOYSA-N adatanserin Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NCCN(CC1)CCN1C1=NC=CC=N1 HPFLVTSWRFCPCV-UHFFFAOYSA-N 0.000 description 1
• 238000007792 addition Methods 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 229960003148 adinazolam Drugs 0.000 description 1
• GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 description 1
• 208000012826 adjustment disease Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 208000028505 alcohol-related disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 229950009005 altanserin Drugs 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 230000002547 anomalous effect Effects 0.000 description 1
• 229940125713 antianxiety drug Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 201000007201 aphasia Diseases 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 208000030137 articulation disease Diseases 0.000 description 1
• 229960005245 asenapine Drugs 0.000 description 1
• 229940065779 atarax Drugs 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000003935 attention Effects 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 208000029560 autism spectrum disease Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 229950001957 bentazepam Drugs 0.000 description 1
• AIZFEOPQVZBNGH-UHFFFAOYSA-N bentazepam Chemical compound C1=2C=3CCCCC=3SC=2NC(=O)CN=C1C1=CC=CC=C1 AIZFEOPQVZBNGH-UHFFFAOYSA-N 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 208000014679 binge eating disease Diseases 0.000 description 1
• 230000007698 birth defect Effects 0.000 description 1
• 208000024330 bloating Diseases 0.000 description 1
• 231100001015 blood dyscrasias Toxicity 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 208000022266 body dysmorphic disease Diseases 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229940112869 bone morphogenetic protein Drugs 0.000 description 1
• 230000007177 brain activity Effects 0.000 description 1
• 235000021152 breakfast Nutrition 0.000 description 1
• 229950010832 bretazenil Drugs 0.000 description 1
• LWUDDYHYYNNIQI-ZDUSSCGKSA-N bretazenil Chemical compound O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 description 1
• 229960002729 bromazepam Drugs 0.000 description 1
• 229960003051 brotizolam Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 229960000926 camazepam Drugs 0.000 description 1
• PXBVEXGRHZFEOF-UHFFFAOYSA-N camazepam Chemical compound C12=CC(Cl)=CC=C2N(C)C(=O)C(OC(=O)N(C)C)N=C1C1=CC=CC=C1 PXBVEXGRHZFEOF-UHFFFAOYSA-N 0.000 description 1
• 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 208000014486 central sleep apnea syndrome Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 238000000546 chi-square test Methods 0.000 description 1
• 230000035606 childbirth Effects 0.000 description 1
• 229960004782 chlordiazepoxide Drugs 0.000 description 1
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001552 chlorprothixene Drugs 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• NQTRBZXDWMDXAQ-UHFFFAOYSA-N cinazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)C(OC(=O)CCC(=O)O)N=C1C1=CC=CC=C1Cl NQTRBZXDWMDXAQ-UHFFFAOYSA-N 0.000 description 1
• 229960002753 cinolazepam Drugs 0.000 description 1
• XAXMYHMKTCNRRZ-UHFFFAOYSA-N cinolazepam Chemical compound C12=CC(Cl)=CC=C2N(CCC#N)C(=O)C(O)N=C1C1=CC=CC=C1F XAXMYHMKTCNRRZ-UHFFFAOYSA-N 0.000 description 1
• 229960001403 clobazam Drugs 0.000 description 1
• CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• XJRGLCAWBRZUFC-UHFFFAOYSA-N clonazolam Chemical compound C12=CC([N+]([O-])=O)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl XJRGLCAWBRZUFC-UHFFFAOYSA-N 0.000 description 1
• 229960004362 clorazepate Drugs 0.000 description 1
• XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 description 1
• 229960003622 clotiazepam Drugs 0.000 description 1
• 229960003932 cloxazolam Drugs 0.000 description 1
• ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000001427 coherent effect Effects 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 208000030251 communication disease Diseases 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 238000011970 concomitant therapy Methods 0.000 description 1
• 229940124301 concurrent medication Drugs 0.000 description 1
• 230000009514 concussion Effects 0.000 description 1
• 238000007596 consolidation process Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 208000012839 conversion disease Diseases 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
• 229960001140 cyproheptadine Drugs 0.000 description 1
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
• 238000013498 data listing Methods 0.000 description 1
• 229950007393 delorazepam Drugs 0.000 description 1
• CHIFCDOIPRCHCF-UHFFFAOYSA-N delorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl CHIFCDOIPRCHCF-UHFFFAOYSA-N 0.000 description 1
• 208000010934 demyelinating disease of central nervous system Diseases 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 229950011405 deramciclane Drugs 0.000 description 1
• UVCOILFBWYKHHB-UHFFFAOYSA-N desalkylflurazepam Chemical compound FC1=CC=CC=C1C1=NCC(=O)NC2=CC=C(Cl)C=C12 UVCOILFBWYKHHB-UHFFFAOYSA-N 0.000 description 1
• 229950005407 desalkylflurazepam Drugs 0.000 description 1
• JIOBORXCOGMHSV-UHFFFAOYSA-N deschloroetizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1 JIOBORXCOGMHSV-UHFFFAOYSA-N 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 210000000188 diaphragm Anatomy 0.000 description 1
• 230000003205 diastolic effect Effects 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• VPAYQWRBBOGGPY-UHFFFAOYSA-N diclazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl VPAYQWRBBOGGPY-UHFFFAOYSA-N 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 208000018459 dissociative disease Diseases 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000035622 drinking Effects 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 235000006694 eating habits Nutrition 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 230000008909 emotion recognition Effects 0.000 description 1
• 230000010491 emotional process Effects 0.000 description 1
• 230000006397 emotional response Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 210000001353 entorhinal cortex Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 230000001073 episodic memory Effects 0.000 description 1
• 229960002336 estazolam Drugs 0.000 description 1
• CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
• 229950004336 ethyl carfluzepate Drugs 0.000 description 1
• PUJLIQLPZOZCOP-UHFFFAOYSA-N ethyl carfluzepate Chemical compound C12=CC(Cl)=CC=C2N(C(=O)NC)C(=O)C(C(=O)OCC)N=C1C1=CC=CC=C1F PUJLIQLPZOZCOP-UHFFFAOYSA-N 0.000 description 1
• 229960004759 ethyl loflazepate Drugs 0.000 description 1
• 229960004404 etizolam Drugs 0.000 description 1
• 229960005437 etoperidone Drugs 0.000 description 1
• IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
• 210000000887 face Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• ZRKDDZBVSZLOFS-UHFFFAOYSA-N flubromazepam Chemical compound FC1=CC=CC=C1C1=NCC(=O)NC2=CC=C(Br)C=C12 ZRKDDZBVSZLOFS-UHFFFAOYSA-N 0.000 description 1
• VXGSZBZQCBNUIP-UHFFFAOYSA-N flubromazolam Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1F VXGSZBZQCBNUIP-UHFFFAOYSA-N 0.000 description 1
• 229960002200 flunitrazepam Drugs 0.000 description 1
• 229960003528 flurazepam Drugs 0.000 description 1
• SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
• 229950009354 flutazolam Drugs 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 238000012395 formulation development Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229960002158 halazepam Drugs 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 231100001261 hazardous Toxicity 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229960000930 hydroxyzine Drugs 0.000 description 1
• 239000003326 hypnotic agent Substances 0.000 description 1
• 230000000147 hypnotic effect Effects 0.000 description 1
• 208000017020 hypoactive sexual desire disease Diseases 0.000 description 1
• 208000034783 hypoesthesia Diseases 0.000 description 1
• 239000002117 illicit drug Substances 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 208000015046 intermittent explosive disease Diseases 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
• 229960005417 ketanserin Drugs 0.000 description 1
• 229960004423 ketazolam Drugs 0.000 description 1
• PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
• 206010023461 kleptomania Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 230000008449 language Effects 0.000 description 1
• 208000011977 language disease Diseases 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 235000007635 levomefolic acid Nutrition 0.000 description 1
• 239000011578 levomefolic acid Substances 0.000 description 1
• 210000004558 lewy body Anatomy 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000007477 logistic regression Methods 0.000 description 1
• 229960003019 loprazolam Drugs 0.000 description 1
• UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
• 229960004033 lormetazepam Drugs 0.000 description 1
• HTODIQZHVCHVGM-JTQLQIEISA-N lubazodone Chemical compound C1=2CCCC=2C(F)=CC=C1OC[C@@H]1CNCCO1 HTODIQZHVCHVGM-JTQLQIEISA-N 0.000 description 1
• 229950004415 lubazodone Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229950002184 meclonazepam Drugs 0.000 description 1
• 229960002225 medazepam Drugs 0.000 description 1
• 229960003123 medifoxamine Drugs 0.000 description 1
• QNMGHBMGNRQPNL-UHFFFAOYSA-N medifoxamine Chemical compound C=1C=CC=CC=1OC(CN(C)C)OC1=CC=CC=C1 QNMGHBMGNRQPNL-UHFFFAOYSA-N 0.000 description 1
• 229960001861 melperone Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004914 menses Anatomy 0.000 description 1
• DOTIMEKVTCOGED-UHFFFAOYSA-N mepiprazole Chemical compound N1C(C)=CC(CCN2CCN(CC2)C=2C=C(Cl)C=CC=2)=N1 DOTIMEKVTCOGED-UHFFFAOYSA-N 0.000 description 1
• 229950004808 mepiprazole Drugs 0.000 description 1
• 229950008693 mesulergine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
• 229960004650 metergoline Drugs 0.000 description 1
• ANUCDXCTICZJRH-UHFFFAOYSA-N mexazolam Chemical compound C=1C=C(Cl)C=C2C=1NC(=O)CN1C(C)COC21C1=CC=CC=C1Cl ANUCDXCTICZJRH-UHFFFAOYSA-N 0.000 description 1
• 229950000412 mexazolam Drugs 0.000 description 1
• 229960003955 mianserin Drugs 0.000 description 1
• 229960003793 midazolam Drugs 0.000 description 1
• DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
• 229960001785 mirtazapine Drugs 0.000 description 1
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
• 208000027881 multiple personality disease Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• QOBGWWQAMAPULA-RLLQIKCJSA-N n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 QOBGWWQAMAPULA-RLLQIKCJSA-N 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 229960001800 nefazodone Drugs 0.000 description 1
• VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 208000008795 neuromyelitis optica Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 229960002686 niaprazine Drugs 0.000 description 1
• RSKQGBFMNPDPLR-UHFFFAOYSA-N niaprazine Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCN(CC1)CCN1C1=CC=C(F)C=C1 RSKQGBFMNPDPLR-UHFFFAOYSA-N 0.000 description 1
• GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
• 229950001981 nimetazepam Drugs 0.000 description 1
• KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
• 229960001454 nitrazepam Drugs 0.000 description 1
• 239000000820 nonprescription drug Substances 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 229960002640 nordazepam Drugs 0.000 description 1
• AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• 208000024196 oppositional defiant disease Diseases 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 235000020830 overeating Nutrition 0.000 description 1
• 229960004535 oxazepam Drugs 0.000 description 1
• ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229960001057 paliperidone Drugs 0.000 description 1
• 208000002851 paranoid schizophrenia Diseases 0.000 description 1
• 208000012198 paraphilic disease Diseases 0.000 description 1
• 239000006201 parenteral dosage form Substances 0.000 description 1
• 235000019546 parosmia Nutrition 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 208000022821 personality disease Diseases 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 238000010587 phase diagram Methods 0.000 description 1
• 229940049721 phenazepam Drugs 0.000 description 1
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
• 229960003418 phenoxybenzamine Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 230000003863 physical function Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 1
• 229960002034 pinazepam Drugs 0.000 description 1
• MFZOSKPPVCIFMT-UHFFFAOYSA-N pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 description 1
• FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
• 229960004572 pizotifen Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000009597 pregnancy test Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• CNWSHOJSFGGNLC-UHFFFAOYSA-N premazepam Chemical compound C=1N(C)C(C)=C2C=1NC(=O)CN=C2C1=CC=CC=C1 CNWSHOJSFGGNLC-UHFFFAOYSA-N 0.000 description 1
• 229950003432 premazepam Drugs 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 229950003077 pruvanserin Drugs 0.000 description 1
• KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
• 229960003908 pseudoephedrine Drugs 0.000 description 1
• 229940124811 psychiatric drug Drugs 0.000 description 1
• 230000009430 psychological distress Effects 0.000 description 1
• 230000008433 psychological processes and functions Effects 0.000 description 1
• BGRWSFIQQPVEML-UHFFFAOYSA-N pyrazolam Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=N1 BGRWSFIQQPVEML-UHFFFAOYSA-N 0.000 description 1
• 201000004645 pyromania Diseases 0.000 description 1
• 238000000306 qrs interval Methods 0.000 description 1
• 238000000275 quality assurance Methods 0.000 description 1
• 229960001964 quazepam Drugs 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 1
• 238000013102 re-test Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 238000013468 resource allocation Methods 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 201000009570 retrograde amnesia Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 190000007496 rilmazafone Chemical compound 0.000 description 1
• 229950002503 rilmazafone Drugs 0.000 description 1
• JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
• 229950009626 ritanserin Drugs 0.000 description 1
• 102200143520 rs6265 Human genes 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 229950005789 sarpogrelate Drugs 0.000 description 1
• FFYNAVGJSYHHFO-UHFFFAOYSA-N sarpogrelate Chemical compound COC1=CC=CC(CCC=2C(=CC=CC=2)OCC(CN(C)C)OC(=O)CCC(O)=O)=C1 FFYNAVGJSYHHFO-UHFFFAOYSA-N 0.000 description 1
• 208000022610 schizoaffective disease Diseases 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 238000010206 sensitivity analysis Methods 0.000 description 1
• 208000025874 separation anxiety disease Diseases 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000003727 serotonin 1A antagonist Substances 0.000 description 1
• 239000002400 serotonin 2A antagonist Substances 0.000 description 1
• 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
• 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
• 229950009024 setoperone Drugs 0.000 description 1
• RBGAHDDQSRBDOG-UHFFFAOYSA-N setoperone Chemical compound CC=1N=C2SCCN2C(=O)C=1CCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 RBGAHDDQSRBDOG-UHFFFAOYSA-N 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 230000036299 sexual function Effects 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 230000037321 sleepiness Effects 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 230000006886 spatial memory Effects 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 230000009295 sperm incapacitation Effects 0.000 description 1
• 229950001675 spiperone Drugs 0.000 description 1
• DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 229940071117 starch glycolate Drugs 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229960003188 temazepam Drugs 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• 229940127228 tetracyclic antidepressant Drugs 0.000 description 1
• IQWYAQCHYZHJOS-UHFFFAOYSA-N tetrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CCCCC1 IQWYAQCHYZHJOS-UHFFFAOYSA-N 0.000 description 1
• 229960005214 tetrazepam Drugs 0.000 description 1
• 231100000886 tinnitus Toxicity 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000133 toxic exposure Toxicity 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000009898 traumatic memory Effects 0.000 description 1
• 229960003991 trazodone Drugs 0.000 description 1
• PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
• 229960003386 triazolam Drugs 0.000 description 1
• 208000002271 trichotillomania Diseases 0.000 description 1
• 229940072651 tylenol Drugs 0.000 description 1
• 229940116269 uric acid Drugs 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000010330 visuo-spatial memory Effects 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1
• JRYTUFKIORWTNI-UHFFFAOYSA-N xylamidine Chemical compound COC1=CC=CC(OC(C)CN=C(N)CC=2C=C(C)C=CC=2)=C1 JRYTUFKIORWTNI-UHFFFAOYSA-N 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
• 229960000820 zopiclone Drugs 0.000 description 1
• 229960004496 zotepine Drugs 0.000 description 1
• HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1